Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
Globe Newswire•08/10/2026•07:30 ET
0
Key Highlights
- ➤Florida Blue agreement adds approximately 6 million covered lives to CNSide’s payer footprint
- ➤CNSide contracted payer agreements now represent approximately 164 million covered lives
- ➤Agreement covers CNSide CSF Tumor Cell Enumeration and Molecular Profile tests
- ➤CNSide CSF Molecular Profile tests are now commercially available through CNSide
- ➤More than 11,000 CNSide tests performed at over 120 U.S. cancer institutions since 2020
Expert Statements
Marc Hedrick, M.D., President and Chief Executive Officer of Cerenome
“This agreement with Florida Blue represents an important milestone in CNSide’s commercial trajectory”
Marc Hedrick, M.D., President and Chief Executive Officer of Cerenome
“By expanding contracted reimbursement to both cellular and molecular CSF testing, we are advancing CNSide as a broader CSF diagnostics platform for CNS oncology, combining tumor-cell analysis and molecular profiling to better characterize and monitor cancers involving the central nervous system.”
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration
Expands CNSide contracted payer access to approximately 164 million covered lives
Get started
Create a free account to read the full story.